

FORM PTO-1449 (modified)  
To: U.S. Department of Commerce  
(PW FORM PAT-1449)  
Patent and Trademark Office

Cont. #

C-M#

3217

043043-0359294

Fat Reducing Antibody

Applicant: Heinz Peter Vollmers

Appln. No.: 10/578,856

Filing Date: July 18, 2006

Examiner: Saoud, Christine J. Art Unit: 1647

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

Date: October 22, 2009

Page

1

of

6

## **U.S. PATENT DOCUMENTS**

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
<del>AR</del>	<del>2005/0123571 A1</del>	<del>06/2005</del>	<del>Rossini, et al.</del>			
<del>BB</del>	<del>5,610,280</del>	<del>03/1997</del>	<del>Brandt, et al.</del>			
<del>CB</del>	<del>5,630,863</del>	<del>06/1997</del>	<del>Dan</del>			
<del>DR</del>	<del>5,783,224</del>	<del>06/1998</del>	<del>Caras, et al.</del>			
<del>ER</del>	<del>6,677,442 B1</del>	<del>1/2004</del>	<del>Wang, et al.</del>			
<del>FR</del>	<del>6,995,240 B1</del>	<del>02/2006</del>	<del>Panayi, et al.</del>			
<del>GR</del>	<del>7,040,102 B1</del>	<del>05/2008</del>	<del>Lee</del>			

## **FOREIGN PATENT DOCUMENTS**

Examiner's Initials*	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
					Enclosed	No	Enclosed	No
<del>HR</del>	<del>4107154 A1</del>	<del>04/1992</del>	<del>DE</del>	<del>Brandt, et al. (German)</del>				
<del>IR</del>	<del>10230510 A1</del>	<del>01/2004</del>	<del>DE</del>	<del>Müller-Hermelink, et al.</del>				
<del>JR</del>	<del>69212671 T2</del>	<del>03/1997</del>	<del>DE</del>	<del>Weiss, et al. (German)</del>				
<del>KR</del>	<del>69220110 T3</del>	<del>11/1999</del>	<del>DE</del>	<del>Gram, et al. (German)</del>				
<del>LR</del>	<del>09527975 T2</del>	<del>09/2000</del>	<del>DE</del>	<del>Ellis, et al. (German)</del>				
<del>MR</del>	<del>1100109 A2</del>	<del>00/2001</del>	<del>EP</del>	<del>Fendly</del>				
<del>NR</del>	<del>1141019 B1</del>	<del>04/2004</del>	<del>EP</del>	<del>Vollmers et al. (German)</del>				
<del>OR</del>	<del>00/012562</del>	<del>03/2000</del>	<del>WO</del>	<del>Adams, et al.</del>				
<del>PR</del>	<del>00/37489 A3</del>	<del>06/2000</del>	<del>WO</del>	<del>Vollmers et al. (German)</del>				
<del>QR</del>	<del>00/37489 A2</del>	<del>06/2000</del>	<del>WO</del>	<del>Vollmers et al. (German)</del>				
<del>RR</del>	<del>01/02932 A1</del>	<del>08/2001</del>	<del>WO</del>	<del>Deshpande, et al.</del>				
<del>SR</del>	<del>01/03560 A1</del>	<del>11/2001</del>	<del>WO</del>	<del>Zhou, et al.</del>				
<del>TR</del>	<del>02/02641 A1</del>	<del>01/2002</del>	<del>WO</del>	<del>Cambridge Antibody Tech., Vaughn Tristan</del>				
<del>UR</del>	<del>02/084277 A1</del>	<del>10/2002</del>	<del>WO</del>	<del>Lee</del>				
<del>VR</del>	<del>02/42582 A2</del>	<del>02/2002</del>	<del>WO</del>	<del>Giles-Komar, et al.</del>				
<del>WR</del>	<del>03/014007 A3</del>	<del>02/2003</del>	<del>WO</del>	<del>Mueller-Hermelink et al.</del>				
<del>XR</del>	<del>2005/070472 A2</del>	<del>09/2003</del>	<del>WO</del>	<del>Vollmers, et al.</del>				

Examiner

Date Considered:

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

references lined through as they are duplicates and have already been considered. /C.S./

FORM PTO-1449 (modified)  
To: U.S. Department of Commerce  
(PW FORM PAT-1449)  
Patent and Trademark Office

Cont. #	C-M#	
	043043-0359294	Fat Reducing Antibody

3217

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

Applicant: Heinz Peter Vollmers

Appln. No.: 10/578,856

Filing Date: July 18, 2006

Date: October 22, 2009 Page 2 of 6

Examiner: Saoud, Christine J. Art Unit: 1647

## **U.S. PATENT DOCUMENTS**

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
YR						
ZR						
AAR						
BBR						

## **FOREIGN PATENT DOCUMENTS**

Examiner's Initials*	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
					Enclosed	No	Enclosed	No
<del>CCR</del>	<del>2003/070472 A3</del>	<del>09/2003</del>	<del>WO</del>	<del>Vollmers, et al.</del>				
<del>DDR</del>	<del>2004/005951 A2</del>	<del>01/2004</del>	<del>WO</del>	<del>Mueller-Hermelink, et al.</del>				
<del>EER</del>	<del>2004/020999A1</del>	<del>03/2004</del>	<del>WO</del>	<del>Arap, et al.</del>				
<del>FFR</del>	<del>2004/004027 A2</del>	<del>00/2004</del>	<del>WO</del>	<del>Mueller-Hermelink, et al.</del>				
<del>GGR</del>	<del>2004/084027 A3</del>	<del>00/2004</del>	<del>WO</del>	<del>Mueller-Hermelink, et al.</del>				
<del>HHR</del>	<del>2005/001052 A2</del>	<del>01/2005</del>	<del>WO</del>	<del>Rossini, et al.</del>				
<del>IIR</del>	<del>2005/045428 A2</del>	<del>05/2005</del>	<del>WO</del>	<del>Lee, et al.</del>				
<del>JIR</del>	<del>2005/047332 A1</del>	<del>05/2005</del>	<del>WO</del>	<del>Vollmers, et al.</del>				
<del>KKR</del>	<del>2005/065440 A2</del>	<del>07/2005</del>	<del>WO</del>	<del>Pasqualini, et al.</del>				
<del>LLR</del>	<del>2005/085062 A1</del>	<del>09/2005</del>	<del>WO</del>	<del>Charles, et al.</del>				
<del>MMR</del>	<del>2005/092922 A2</del>	<del>10/2005</del>	<del>WO</del>	<del>Vollmers et al.</del>				
<del>NNR</del>	<del>2005/092922 A3</del>	<del>10/2005</del>	<del>WO</del>	<del>Vollmers et al.</del>				
<del>OCR</del>	<del>2005/094159 A2</del>	<del>10/2005</del>	<del>WO</del>	<del>Vollmers et al.</del>				
<del>PPR</del>	<del>97/02470</del>	<del>01/1997</del>	<del>WO</del>	<del>Garen</del>				
<del>QGR</del>	<del>97/13844 A1</del>	<del>04/1997</del>	<del>WO</del>	<del>Thomson et al.</del>				
<del>RRR</del>	<del>99/20401</del>	<del>06/1999</del>	<del>WO</del>	<del>Noteborn, et al.</del>				
				(equivalent to CA 2,312,007 06/2000)				
<del>SSR</del>	<del>99/53051</del>	<del>10/1999</del>	<del>WO</del>	<del>Dumas-Mine-Edwards et al.</del>				
<del>TTT</del>	<del>99/05005 A2</del>	<del>12/1999</del>	<del>WO</del>	<del>Chiodi</del>				
/C.S./	UUR	2005/047332A1	05/2005	WO	Vollmers, et al.			

Examiner /Christine Saoud/ Date Considered: 02/16/2010

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

References lined through as they are duplicates and have already been considered. /C.S./

FORM PTO-1449 (modified)  
To: U.S. Department of Commerce  
(PW FORM PAT-1449)  
Patent and Trademark Office

Conf #

C-M#

3217

043043-0359294

Fat Reducing Antibody

Applicant: Heinz Peter Vollmers

Appln. No.: 10/578,856

Filing Date: July 18, 2006

Examiner: Saoud, Christine J.

Art Unit: 1647

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

Date: October 22, 2009

Page

3

of

6

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

Examiner's

Initials\*

English

Abstract

Translation

Readily

Available

Enclosed

No

Enclosed

No

VVR

Berger, C.L., et al., A Lymphocyte Cell Surface Heat Shock Protein Homologous to the Endoplasmic Reticulum Chaperone, Immunoglobulin Heavy Chain Binding Protein BIP, Int. J. Cancer, 71:1077-1085 (1997)

WWR

Bjorge et al., Complement-Regulatory Proteins in Ovarian Malignancies, Int. J. Cancer, 70:14-25 (1997)

XXR

Brandlein et al., "Natural IgM Antibodies and Immunosurveillance Mechanisms Against Epithelial Cancer Cells in Humans," Cancer Research, 63: 7995-8005, 15 November 2003.

YYR

Brandlein et al., Characterization of Five New Fully Human Monoclonal IgM Antibodies Isolated from Carcinoma Patients, Proceedings of the Annual Meeting of the American Association for Cancer Research 43:970, March 2002 (Abstract)

ZZR

Brandlein et al., Human Monoclonal IgM Antibodies with Apoptotic Activity isolated from Cancer Patients, Human Antibodies 11:107-119, 2002

AAAR

Brandlein, S., et al., CFR-1 Receptor as Target for Tumor-specific Apoptosis Induced by the Natural Human Monoclonal Antibody PAM-1, Oncology Reports, 11:777-784 (2004)

BBBR

Brandlein, S., et al., Cysteine-rich Fibroblast Growth Factor Receptor 1, a New Marker for Precancerous Epithelial Lesions Defined by the Human Monoclonal Antibody PAM-1, Cancer Research, 63:2052-2061 (2003)

CCCR

Brandlein, S., et al., PAM-1, a Natural Human IgM Antibody as New Tool for Detection of Breast and Prostate Precursors, Human Antibodies, 13:97-104 (2004)

DDDR

Chen, G., et al., Protein Profiles Associated With Survival in Lung Adenocarcinoma, [www.pnas.org/cgi/doi/10.1073/pnas.2233850100](http://www.pnas.org/cgi/doi/10.1073/pnas.2233850100) pp. 1-6 (2003)

EEER

Database entry AAB02178 dated June 11, 1996

FFFR

Faller et al., HAB-1, a New Heteromyeloma for Continuous Production of Human Monoclonal Antibodies, Br. J. Cancer 62:595-598 (1990)

Examiner

Date Considered:

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

All references are duplicates and have been previously considered. /C.S./

FORM PTO-1449 (modified) To: U.S. Department of Commerce (PW FORM PAT-1449) Patent and Trademark Office		Conf #	C-M#	
		3217	043043-0359294	Fat Reducing Antibody
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Applicant: Heinz Peter Vollmers		
		Appln. No.: 10/578,856		
		Filing Date: July 18, 2006		
		Examiner: Saoud, Christine J. Art Unit: 1647		
Date: October 22, 2009	Page	4	of	6

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)		English Abstract		Translation Readily Available	
Examiner's Initials*		Enclosed	No	Enclosed	No
GGGR	Gonatas et al., MG-160, A Membrane Sialoglycoprotein of the Medial Cisternae of the Rat Golgi Apparatus, Binds Basic Fibroblast Growth Factor and Exhibits a High level of Sequence Identity to a Chicken Fibroblast Growth Factor Receptor, J. Cell Science 108:457-467, 1995.				
HHHR	Grossman, H.B., Natural Antibody to a Human Bladder Carcinoma Cell Line, Cancer Immunol. Immunother. 13:89-92 (1982)				
IIIR	Hensel et al., A New Variant of Cystein-Rich FGF Receptor (CFR-1) Specifically Expressed on Tumor Cells, Proceedings of the American Association for Cancer Research 41:698 (abstract 4438), March 2000.				
JJJR	Hensel et al., A Novel Proliferation-associated Variant of CFR-1 Defined by a Human Monoclonal Antibody, Laboratory Investigation 81:1097-1108, 2001.				
KKKR	Hensel et al., Characterization of Glycosylphosphatidylinositol-linked Molecule CD55/Decay-accelerating Factor as the Receptor for Antibody SC-1-induced Apoptosis, Cancer Research 59:5299-5306, 1999.				
LLLLR	Hensel et al., Mitogenic Autoantibodies in Helicobacter pylori-Associated Stomach Cancerogenesis, International Journal of Cancer 81:229-235, 1999.				
MMMR	Hensel, F., et al., "Regulation of the new coexpressed CD55 (decay-accelerating factor) receptor on stomach carcinoma cells involved in antibody SC-1-induced apoptosis", Laboratory Investigation, 81(11):1553-1563 (2001)				
NNNR	Huang et al., Sulindac Sulfide-induced Apoptosis Involves Death Receptor 5 and the Caspase 8-dependent Pathway in Human Colon and Prostate Cancer Cells, Cancer Research 61:6918-6924 (2001)				
OOOR	Iwadate, Y., et al., Molecular Classification and Survival Prediction in Human Gliomas Based on Proteome Analysis, Cancer Research, 64:2496-2501 (2004)				
PPPR	Jamora, C., et al., Inhibition of Tumor Progression by Suppression of Stress Protein GRP78/BiP Induction in Fibrosarcoma B/C10ME, Proc. Natl. Acad. Sci. USA, 93:7690-7694 (1996)				
QQQR	Jansson, et al., The Human Repertoire of Antibody Specificities Against Thomsen-Friedenreich and TN-carcinoma-associated antigens as defined by Monoclonal Antibodies, Cancer Immunology 34:294-298, 1992.				

Examiner	Date Considered:
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

All references are duplicates and have been previously considered. /C.S./

FORM PTO-1449 (modified)  
To: U.S. Department of Commerce  
(PW FORM PAT-1449)  
Patent and Trademark Office

Conf #

C-M#

3217

043043-0359294

Fat Reducing Antibody

Applicant: Heinz Peter Vollmers

Appln. No.: 10/578,856

Filing Date: July 18, 2006

Examiner: Saoud, Christine J.

Art Unit: 1647

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

Date: October 22, 2009

Page

5

of

6

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

Examiner's

Initials\*

English  
Abstract

Translation  
Readily  
Available

Enclosed

No

Enclosed

No

RRRR	Kamitani, H., et al., Expression of 15-Lipoxygenase by Human Colorectal Carcinoma Caco-2 Cells During Apoptosis and Cell Differentiation, The Journal of Biological Chemistry, 273(34):21569-21577 (1998)
SSSR	Lee, A.S., Mammalian Stress Response: Induction of the Glucose-Regulated Protein Family, Current Opinion in Cell Biology, 4:267-273 (1992)
TTTR	Little, E., et al., The Glucose-Regulated Proteins (GRP78 and GRP94): Functions, Gene Regulation, and Applications, Critical Reviews In Eukaryonic Gene Expression, 4(1):1-18 (1994)
UUUR	Liu et al., Towards Proteome-Wide Production of Monoclonal Antibody by Phage Display, J. Mol. Bio. 315:1063-1073 (2002)
VVVR	Mammalian Gene Collection (MGC) Program Team, "Generation and Initial Analysis of more than 15,000 Full-Length Human and Mouse cDNA Sequences" PNAS USA 99:16,899-16,903 (2002)
WWWI	Masatoshi, K., Antibody CDNA, Abstract JP Publication No. 09098786 0, 04/15/1997
XXXR	Mintz, P.J., et al., Fingerprinting the Circulating Repertoire of Antibodies from Cancer Patients, Nature Biotechnology, 21:57-63 (2003)
YYR	Misra, U.K., et al., The Role of Grp 78 in $\alpha_2$ -Macroglobulin-Induced Signal Transduction, The Journal of Biological Chemistry, 277(44):42082-42087 (2002)
ZZZR	Mourelatos et al., Cloning and Sequence Analysis of the Human MG160, a Fibroblast Growth Factor and E-Selectin Binding Membrane Sialoglycoprotein of the Golgi Apparatus, DNA Cell Biol. 12:1121-1128 (1996)
AAAA	Myung, J-K, et al., Expressional Patterns of Chaperones in Ten Human Tumor Cell Lines, Proteome Science, 2:8:1-21 (2004)
BBBB	Pfaff, M., et al., Human Monoclonal Antibody Against a Tissue Polypeptide Antigen-related Protein from a Patient with a Signet-Ring Cell Carcinoma of the Stomach, Cancer Research, 50:5192-5198 (1990)
CCCC	Pohle et al., Lipoptosis: Tumor Specific Cell Death by Antibody-Induced Intracellular Lipid Accumulation, Cancer Research, 64:11, 3900-3906 (2004)

Examiner

Date Considered:

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

All references are duplicates and have been previously considered. /C.S./

FORM PTO-1449 (modified)  
To: U.S. Department of Commerce  
(PW FORM PAT-1449)  
Patent and Trademark Office

Conf #	C-M#	
3217	043043-0359294	Fat Reducing Antibody

Applicant: Heinz Peter Vollmers	
Appln. No.: 10/578,856	
Filing Date: July 18, 2006	
Examiner: Saoud, Christine J.	Art Unit: 1647

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

Date: October 22, 2009 Page 

6
---

 of 

6
---

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)		English Abstract		Translation Readily Available	
Examiner's Initials*		Enclosed	No	Enclosed	No
<del>DDDD</del>	<del>Sato, K., et al., Immunotherapy Using Heat-Shock Protein Preparations of Leukemia Cells After Syngenic Bone Marrow Transplantation in Mice, Blood, 98(6):1852-1857 (2001)</del>				
<del>EEEE</del>	<del>Sugawara, G., et al., Suppression of Stress Protein GRP78 Induction in Tumor B/C10ME Eliminates Resistance to Cell Mediated Cytotoxicity, Cancer Research, 53:6001-6005 (1993)</del>				
<del>FFFF</del>	<del>Timmermann W., et al., Immuntherapie: ein Antikörper gegen Magenkrebs" Blick 1/1999, Artikel 6, internet page <a href="http://www.uni-wuerzburg.de/blick1999-1/991do6-t.html">http://www.uni-wuerzburg.de/blick1999-1/991do6-t.html</a>.</del>				
<del>GGGG</del>	<del>Vollmers et al., "Apoptosis of Stomach Carcinoma Cells Induced by a Human Monoclonal Antibody," Cancer 76:550-558 (1995).</del>				
<del>HHHH</del>	<del>Vollmers et al., "Human Monoclonal Antibodies from Stomach Carcinoma Patients React with <i>Helicobacter pylori</i> and Stimulate Stomach Cells <i>in vitro</i>," Cancer 74:1525-1532, 1994.</del>				
<del>IIIR</del>	<del>Vollmers et al., "SC-1, a Functional Human Monoclonal Antibody against Autologous Stomach Carcinoma Cells," Cancer Res. 49:2471-2476, 1989.</del>				
<del>JJJJ</del>	<del>Vollmers et al., Adjuvant Therapy for Gastric Adenocarcinoma with the Apoptosis-Inducing Human Monoclonal Antibody SC-1: First Clinical and Histopathological Results, Oncology Reports 5:549-552 (1998)</del>				
<del>KKKK</del>	<del>Vollmers, H.P., et al., Monoclonal Antibodies NORM-1 and NORM-2 Induce More Normal Behavior of Tumor Cells <i>In Vitro</i> and Reduce Tumor Growth <i>In Vivo</i>, Cell, 40:547-557 (1985).</del>				
<del>LLLL</del>	<del>Vollmers, P., et al., Tumor-Specific Apoptosis Induced by the Human Monoclonal Antibody SC-1: A New Therapeutic Approach for Stomach Cancer, Oncology Reports, 5:35-40 (1998)</del>				
<del>MMMM</del>	<del>Wixler et al., "Identification of Novel Interaction Partners for the conserved membrane proximal region of alpha-integrin cytoplasmic domains," FEBS Letters vol. 445, 26 Feb 1999.</del>				
/C.S./	NNNN Mueller-Hermelink, et al., Application No. 10/579,290, "Adenocarcinoma Specific Antibody SAM-6, and Uses Thereof", 05/15/2006				
/C.S./	OOOO Vollmers, Heinz Peter, Application No. 11/945,916, "Novel Glycosylated Peptide Target in Neoplastic Cells", 11/27/2007				
	PPPP				
	QQQQ				

Examiner /Christine Saoud/	Date Considered: 02/16/2010
----------------------------	-----------------------------

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**lined through references have been previously submitted and considered./C.S./**